nodes	percent_of_prediction	percent_of_DWPC	metapath
Dopamine—HTR7—vas deferens—urinary bladder cancer	0.0495	0.172	CbGeAlD
Dopamine—SLC22A2—Cisplatin—urinary bladder cancer	0.0384	0.413	CbGbCtD
Dopamine—Gangrene—Gemcitabine—urinary bladder cancer	0.0179	0.094	CcSEcCtD
Dopamine—Extravasation—Carboplatin—urinary bladder cancer	0.0143	0.0748	CcSEcCtD
Dopamine—CYP1A2—Fluorouracil—urinary bladder cancer	0.0138	0.148	CbGbCtD
Dopamine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0124	0.133	CbGbCtD
Dopamine—DBH—prostate gland—urinary bladder cancer	0.012	0.0418	CbGeAlD
Dopamine—CYP2C19—urine—urinary bladder cancer	0.012	0.0418	CbGeAlD
Dopamine—Necrosis—Mitomycin—urinary bladder cancer	0.0118	0.0618	CcSEcCtD
Dopamine—CYP1A2—Etoposide—urinary bladder cancer	0.0115	0.123	CbGbCtD
Dopamine—Extravasation—Mitomycin—urinary bladder cancer	0.0106	0.0556	CcSEcCtD
Dopamine—CYP2C9—Cisplatin—urinary bladder cancer	0.0105	0.113	CbGbCtD
Dopamine—CYP1A2—urine—urinary bladder cancer	0.00981	0.0341	CbGeAlD
Dopamine—CYP2C9—urine—urinary bladder cancer	0.00932	0.0324	CbGeAlD
Dopamine—CYP2D6—urine—urinary bladder cancer	0.00699	0.0243	CbGeAlD
Dopamine—DBH—female reproductive system—urinary bladder cancer	0.00657	0.0228	CbGeAlD
Dopamine—CYP2D6—Doxorubicin—urinary bladder cancer	0.00645	0.0694	CbGbCtD
Dopamine—COMT—prostate gland—urinary bladder cancer	0.00636	0.0221	CbGeAlD
Dopamine—SLC22A2—renal system—urinary bladder cancer	0.0054	0.0188	CbGeAlD
Dopamine—ADRB1—prostate gland—urinary bladder cancer	0.00539	0.0187	CbGeAlD
Dopamine—COMT—seminal vesicle—urinary bladder cancer	0.00538	0.0187	CbGeAlD
Dopamine—SLC22A3—prostate gland—urinary bladder cancer	0.00535	0.0186	CbGeAlD
Dopamine—Extravasation—Thiotepa—urinary bladder cancer	0.00533	0.028	CcSEcCtD
Dopamine—DRD5—female reproductive system—urinary bladder cancer	0.00505	0.0176	CbGeAlD
Dopamine—MAOB—prostate gland—urinary bladder cancer	0.00495	0.0172	CbGeAlD
Dopamine—Necrosis—Fluorouracil—urinary bladder cancer	0.00491	0.0257	CcSEcCtD
Dopamine—Cyanosis—Etoposide—urinary bladder cancer	0.00472	0.0248	CcSEcCtD
Dopamine—Necrosis—Cisplatin—urinary bladder cancer	0.00465	0.0244	CcSEcCtD
Dopamine—SLC22A3—seminal vesicle—urinary bladder cancer	0.00452	0.0157	CbGeAlD
Dopamine—COMT—smooth muscle tissue—urinary bladder cancer	0.0045	0.0157	CbGeAlD
Dopamine—Extravasation—Gemcitabine—urinary bladder cancer	0.00449	0.0235	CcSEcCtD
Dopamine—Extravasation—Fluorouracil—urinary bladder cancer	0.00441	0.0231	CcSEcCtD
Dopamine—COMT—renal system—urinary bladder cancer	0.00434	0.0151	CbGeAlD
Dopamine—Mesalazine—MPO—urinary bladder cancer	0.00427	0.368	CrCbGaD
Dopamine—Necrosis—Etoposide—urinary bladder cancer	0.00426	0.0223	CcSEcCtD
Dopamine—COMT—urethra—urinary bladder cancer	0.00426	0.0148	CbGeAlD
Dopamine—MAOA—prostate gland—urinary bladder cancer	0.00422	0.0147	CbGeAlD
Dopamine—MAOB—seminal vesicle—urinary bladder cancer	0.00419	0.0145	CbGeAlD
Dopamine—Extravasation—Cisplatin—urinary bladder cancer	0.00418	0.0219	CcSEcCtD
Dopamine—SLC22A5—prostate gland—urinary bladder cancer	0.00389	0.0135	CbGeAlD
Dopamine—DBH—lymph node—urinary bladder cancer	0.00384	0.0134	CbGeAlD
Dopamine—Extravasation—Etoposide—urinary bladder cancer	0.00383	0.0201	CcSEcCtD
Dopamine—SLC22A1—renal system—urinary bladder cancer	0.00381	0.0133	CbGeAlD
Dopamine—Mesalazine—PPARG—urinary bladder cancer	0.00379	0.327	CrCbGaD
Dopamine—SLC22A3—smooth muscle tissue—urinary bladder cancer	0.00379	0.0132	CbGeAlD
Dopamine—Azotaemia—Methotrexate—urinary bladder cancer	0.00376	0.0197	CcSEcCtD
Dopamine—SLC22A3—renal system—urinary bladder cancer	0.00365	0.0127	CbGeAlD
Dopamine—SLC22A3—urethra—urinary bladder cancer	0.00358	0.0124	CbGeAlD
Dopamine—MAOA—seminal vesicle—urinary bladder cancer	0.00357	0.0124	CbGeAlD
Dopamine—Hypertension—Mitomycin—urinary bladder cancer	0.00349	0.0183	CcSEcCtD
Dopamine—COMT—female reproductive system—urinary bladder cancer	0.00347	0.0121	CbGeAlD
Dopamine—MAOB—renal system—urinary bladder cancer	0.00337	0.0117	CbGeAlD
Dopamine—MAOB—urethra—urinary bladder cancer	0.00331	0.0115	CbGeAlD
Dopamine—SLC22A5—seminal vesicle—urinary bladder cancer	0.00329	0.0114	CbGeAlD
Dopamine—HTR7—epithelium—urinary bladder cancer	0.00325	0.0113	CbGeAlD
Dopamine—HTR1A—renal system—urinary bladder cancer	0.00315	0.0109	CbGeAlD
Dopamine—COMT—vagina—urinary bladder cancer	0.00314	0.0109	CbGeAlD
Dopamine—HTR7—smooth muscle tissue—urinary bladder cancer	0.00313	0.0109	CbGeAlD
Dopamine—Vomiting—Valrubicin—urinary bladder cancer	0.00305	0.016	CcSEcCtD
Dopamine—HTR7—renal system—urinary bladder cancer	0.00301	0.0105	CbGeAlD
Dopamine—Headache—Valrubicin—urinary bladder cancer	0.003	0.0157	CcSEcCtD
Dopamine—Dyspnoea—Mitomycin—urinary bladder cancer	0.00294	0.0154	CcSEcCtD
Dopamine—ADRB1—female reproductive system—urinary bladder cancer	0.00294	0.0102	CbGeAlD
Dopamine—SLC22A3—female reproductive system—urinary bladder cancer	0.00292	0.0101	CbGeAlD
Dopamine—MAOA—renal system—urinary bladder cancer	0.00288	0.01	CbGeAlD
Dopamine—Nausea—Valrubicin—urinary bladder cancer	0.00285	0.0149	CcSEcCtD
Dopamine—SLC6A4—female reproductive system—urinary bladder cancer	0.00284	0.00988	CbGeAlD
Dopamine—Cyanosis—Methotrexate—urinary bladder cancer	0.00283	0.0148	CcSEcCtD
Dopamine—MAOA—urethra—urinary bladder cancer	0.00283	0.00983	CbGeAlD
Dopamine—SLC22A1—vagina—urinary bladder cancer	0.00276	0.0096	CbGeAlD
Dopamine—MAOB—female reproductive system—urinary bladder cancer	0.0027	0.00939	CbGeAlD
Dopamine—SLC22A5—renal system—urinary bladder cancer	0.00265	0.00921	CbGeAlD
Dopamine—SLC22A3—vagina—urinary bladder cancer	0.00264	0.00918	CbGeAlD
Dopamine—SLC22A5—urethra—urinary bladder cancer	0.0026	0.00905	CbGeAlD
Dopamine—Necrosis—Methotrexate—urinary bladder cancer	0.00255	0.0134	CcSEcCtD
Dopamine—Ventricular arrhythmia—Epirubicin—urinary bladder cancer	0.00253	0.0133	CcSEcCtD
Dopamine—SLC6A2—female reproductive system—urinary bladder cancer	0.0025	0.00869	CbGeAlD
Dopamine—MAOB—vagina—urinary bladder cancer	0.00244	0.00849	CbGeAlD
Dopamine—HTR7—female reproductive system—urinary bladder cancer	0.00241	0.00838	CbGeAlD
Dopamine—CYP1A2—renal system—urinary bladder cancer	0.0024	0.00835	CbGeAlD
Dopamine—Necrosis—Epirubicin—urinary bladder cancer	0.00239	0.0125	CcSEcCtD
Dopamine—Angina pectoris—Fluorouracil—urinary bladder cancer	0.00235	0.0123	CcSEcCtD
Dopamine—Ventricular arrhythmia—Doxorubicin—urinary bladder cancer	0.00234	0.0123	CcSEcCtD
Dopamine—MAOA—female reproductive system—urinary bladder cancer	0.00231	0.00801	CbGeAlD
Dopamine—Extravasation—Methotrexate—urinary bladder cancer	0.0023	0.012	CcSEcCtD
Dopamine—Necrosis—Doxorubicin—urinary bladder cancer	0.00221	0.0116	CcSEcCtD
Dopamine—Extravasation—Epirubicin—urinary bladder cancer	0.00215	0.0113	CcSEcCtD
Dopamine—CYP2C19—vagina—urinary bladder cancer	0.00213	0.0074	CbGeAlD
Dopamine—SLC22A5—female reproductive system—urinary bladder cancer	0.00212	0.00738	CbGeAlD
Dopamine—Vomiting—Mitomycin—urinary bladder cancer	0.0021	0.011	CcSEcCtD
Dopamine—MAOA—vagina—urinary bladder cancer	0.00208	0.00724	CbGeAlD
Dopamine—Headache—Mitomycin—urinary bladder cancer	0.00207	0.0108	CcSEcCtD
Dopamine—COMT—lymph node—urinary bladder cancer	0.00203	0.00706	CbGeAlD
Dopamine—Extravasation—Doxorubicin—urinary bladder cancer	0.00199	0.0104	CcSEcCtD
Dopamine—Nausea—Mitomycin—urinary bladder cancer	0.00196	0.0103	CcSEcCtD
Dopamine—Epinephrine—TNF—urinary bladder cancer	0.00194	0.167	CrCbGaD
Dopamine—SLC22A5—vagina—urinary bladder cancer	0.00192	0.00667	CbGeAlD
Dopamine—Bradycardia—Cisplatin—urinary bladder cancer	0.00187	0.00978	CcSEcCtD
Dopamine—CYP2C9—female reproductive system—urinary bladder cancer	0.00183	0.00634	CbGeAlD
Dopamine—Hypertension—Thiotepa—urinary bladder cancer	0.00176	0.00921	CcSEcCtD
Dopamine—Anxiety—Thiotepa—urinary bladder cancer	0.00173	0.00905	CcSEcCtD
Dopamine—CYP2D6—renal system—urinary bladder cancer	0.00171	0.00594	CbGeAlD
Dopamine—SLC22A3—lymph node—urinary bladder cancer	0.00171	0.00594	CbGeAlD
Dopamine—Tachycardia—Thiotepa—urinary bladder cancer	0.00162	0.0085	CcSEcCtD
Dopamine—Mesalazine—PTGS2—urinary bladder cancer	0.0016	0.138	CrCbGaD
Dopamine—MAOB—lymph node—urinary bladder cancer	0.00158	0.00549	CbGeAlD
Dopamine—Hypertension—Gemcitabine—urinary bladder cancer	0.00148	0.00775	CcSEcCtD
Dopamine—SLC6A2—lymph node—urinary bladder cancer	0.00146	0.00509	CbGeAlD
Dopamine—CYP2D6—female reproductive system—urinary bladder cancer	0.00137	0.00476	CbGeAlD
Dopamine—Anxiety—Cisplatin—urinary bladder cancer	0.00135	0.0071	CcSEcCtD
Dopamine—MAOA—lymph node—urinary bladder cancer	0.00135	0.00469	CbGeAlD
Dopamine—Tachycardia—Fluorouracil—urinary bladder cancer	0.00134	0.00703	CcSEcCtD
Dopamine—Tachycardia—Cisplatin—urinary bladder cancer	0.00127	0.00666	CcSEcCtD
Dopamine—Hypertension—Etoposide—urinary bladder cancer	0.00126	0.00662	CcSEcCtD
Dopamine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00125	0.00653	CcSEcCtD
Dopamine—SLC22A5—lymph node—urinary bladder cancer	0.00124	0.00432	CbGeAlD
Dopamine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00122	0.00642	CcSEcCtD
Dopamine—Tachycardia—Etoposide—urinary bladder cancer	0.00116	0.0061	CcSEcCtD
Dopamine—Dyspnoea—Cisplatin—urinary bladder cancer	0.00116	0.00609	CcSEcCtD
Dopamine—Angina pectoris—Epirubicin—urinary bladder cancer	0.00115	0.00601	CcSEcCtD
Dopamine—Dyspnoea—Etoposide—urinary bladder cancer	0.00106	0.00558	CcSEcCtD
Dopamine—Angina pectoris—Doxorubicin—urinary bladder cancer	0.00106	0.00556	CcSEcCtD
Dopamine—Vomiting—Thiotepa—urinary bladder cancer	0.00106	0.00554	CcSEcCtD
Dopamine—Headache—Thiotepa—urinary bladder cancer	0.00104	0.00546	CcSEcCtD
Dopamine—Nausea—Thiotepa—urinary bladder cancer	0.000986	0.00517	CcSEcCtD
Dopamine—Bradycardia—Epirubicin—urinary bladder cancer	0.000958	0.00502	CcSEcCtD
Dopamine—Vomiting—Gemcitabine—urinary bladder cancer	0.000888	0.00466	CcSEcCtD
Dopamine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000887	0.00465	CcSEcCtD
Dopamine—Headache—Gemcitabine—urinary bladder cancer	0.000875	0.00459	CcSEcCtD
Dopamine—Vomiting—Fluorouracil—urinary bladder cancer	0.000873	0.00458	CcSEcCtD
Dopamine—Headache—Fluorouracil—urinary bladder cancer	0.00086	0.00451	CcSEcCtD
Dopamine—Nausea—Gemcitabine—urinary bladder cancer	0.00083	0.00435	CcSEcCtD
Dopamine—Vomiting—Cisplatin—urinary bladder cancer	0.000828	0.00434	CcSEcCtD
Dopamine—Nausea—Fluorouracil—urinary bladder cancer	0.000816	0.00428	CcSEcCtD
Dopamine—Nausea—Cisplatin—urinary bladder cancer	0.000773	0.00406	CcSEcCtD
Dopamine—Vomiting—Etoposide—urinary bladder cancer	0.000758	0.00398	CcSEcCtD
Dopamine—Headache—Etoposide—urinary bladder cancer	0.000747	0.00392	CcSEcCtD
Dopamine—Palpitations—Epirubicin—urinary bladder cancer	0.000724	0.0038	CcSEcCtD
Dopamine—Nausea—Etoposide—urinary bladder cancer	0.000709	0.00372	CcSEcCtD
Dopamine—Hypertension—Epirubicin—urinary bladder cancer	0.000707	0.00371	CcSEcCtD
Dopamine—Anxiety—Epirubicin—urinary bladder cancer	0.000695	0.00364	CcSEcCtD
Dopamine—Palpitations—Doxorubicin—urinary bladder cancer	0.00067	0.00351	CcSEcCtD
Dopamine—Hypertension—Doxorubicin—urinary bladder cancer	0.000655	0.00343	CcSEcCtD
Dopamine—Tachycardia—Epirubicin—urinary bladder cancer	0.000653	0.00342	CcSEcCtD
Dopamine—Anxiety—Doxorubicin—urinary bladder cancer	0.000643	0.00337	CcSEcCtD
Dopamine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000637	0.00334	CcSEcCtD
Dopamine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000604	0.00317	CcSEcCtD
Dopamine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000596	0.00313	CcSEcCtD
Dopamine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000552	0.00289	CcSEcCtD
Dopamine—Vomiting—Methotrexate—urinary bladder cancer	0.000454	0.00238	CcSEcCtD
Dopamine—Headache—Methotrexate—urinary bladder cancer	0.000448	0.00235	CcSEcCtD
Dopamine—Vomiting—Epirubicin—urinary bladder cancer	0.000425	0.00223	CcSEcCtD
Dopamine—Nausea—Methotrexate—urinary bladder cancer	0.000424	0.00223	CcSEcCtD
Dopamine—Headache—Epirubicin—urinary bladder cancer	0.000419	0.0022	CcSEcCtD
Dopamine—Nausea—Epirubicin—urinary bladder cancer	0.000397	0.00208	CcSEcCtD
Dopamine—Vomiting—Doxorubicin—urinary bladder cancer	0.000393	0.00206	CcSEcCtD
Dopamine—Headache—Doxorubicin—urinary bladder cancer	0.000388	0.00203	CcSEcCtD
Dopamine—Nausea—Doxorubicin—urinary bladder cancer	0.000368	0.00193	CcSEcCtD
Dopamine—ADRB1—Signaling by GPCR—IL2—urinary bladder cancer	3.71e-05	8.9e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—TERT—urinary bladder cancer	3.7e-05	8.87e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—IGF1—urinary bladder cancer	3.68e-05	8.83e-05	CbGpPWpGaD
Dopamine—DRD5—Signaling Pathways—IL2—urinary bladder cancer	3.67e-05	8.81e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—ESR1—urinary bladder cancer	3.67e-05	8.8e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling by GPCR—EGFR—urinary bladder cancer	3.66e-05	8.79e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—RRM2—urinary bladder cancer	3.64e-05	8.73e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—ESR1—urinary bladder cancer	3.62e-05	8.68e-05	CbGpPWpGaD
Dopamine—DRD2—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.59e-05	8.62e-05	CbGpPWpGaD
Dopamine—DRD5—Signaling Pathways—CCND1—urinary bladder cancer	3.58e-05	8.58e-05	CbGpPWpGaD
Dopamine—SLC22A3—Metabolism—EP300—urinary bladder cancer	3.57e-05	8.56e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—CREBBP—urinary bladder cancer	3.57e-05	8.56e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling by GPCR—IL2—urinary bladder cancer	3.55e-05	8.52e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—TERT—urinary bladder cancer	3.54e-05	8.49e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—IGF1—urinary bladder cancer	3.53e-05	8.46e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—NCOR1—urinary bladder cancer	3.52e-05	8.45e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling by GPCR—EGFR—urinary bladder cancer	3.51e-05	8.41e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—NQO1—urinary bladder cancer	3.49e-05	8.37e-05	CbGpPWpGaD
Dopamine—DRD5—Signaling Pathways—MMP9—urinary bladder cancer	3.47e-05	8.33e-05	CbGpPWpGaD
Dopamine—DRD5—Signaling Pathways—CDKN1A—urinary bladder cancer	3.46e-05	8.3e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling by GPCR—KRAS—urinary bladder cancer	3.46e-05	8.3e-05	CbGpPWpGaD
Dopamine—DRD5—Signaling Pathways—PTEN—urinary bladder cancer	3.45e-05	8.29e-05	CbGpPWpGaD
Dopamine—DRD2—GPCR downstream signaling—IL2—urinary bladder cancer	3.43e-05	8.23e-05	CbGpPWpGaD
Dopamine—SLC22A2—Metabolism—PPARG—urinary bladder cancer	3.42e-05	8.21e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—FGFR3—urinary bladder cancer	3.39e-05	8.14e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.38e-05	8.12e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—RHOA—urinary bladder cancer	3.37e-05	8.09e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—ENO2—urinary bladder cancer	3.37e-05	8.09e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	3.37e-05	8.09e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.35e-05	8.04e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling by GPCR—KRAS—urinary bladder cancer	3.31e-05	7.95e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—ESR1—urinary bladder cancer	3.3e-05	7.91e-05	CbGpPWpGaD
Dopamine—DRD5—Signaling Pathways—EP300—urinary bladder cancer	3.29e-05	7.9e-05	CbGpPWpGaD
Dopamine—SLC22A2—Metabolism—CREBBP—urinary bladder cancer	3.29e-05	7.89e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	3.27e-05	7.84e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling by GPCR—CXCL8—urinary bladder cancer	3.26e-05	7.82e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—FGFR3—urinary bladder cancer	3.25e-05	7.79e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—RHOA—urinary bladder cancer	3.23e-05	7.75e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.22e-05	7.72e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—CREBBP—urinary bladder cancer	3.21e-05	7.71e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	3.21e-05	7.69e-05	CbGpPWpGaD
Dopamine—DRD5—Signaling Pathways—SRC—urinary bladder cancer	3.2e-05	7.68e-05	CbGpPWpGaD
Dopamine—SLC22A1—Metabolism—PPARG—urinary bladder cancer	3.19e-05	7.65e-05	CbGpPWpGaD
Dopamine—MAOA—Metabolism—PTGS2—urinary bladder cancer	3.18e-05	7.64e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	3.18e-05	7.63e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—IGF1—urinary bladder cancer	3.17e-05	7.61e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—CREBBP—urinary bladder cancer	3.17e-05	7.61e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling by GPCR—EGFR—urinary bladder cancer	3.16e-05	7.57e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—ESR1—urinary bladder cancer	3.15e-05	7.56e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—IGF1—urinary bladder cancer	3.13e-05	7.51e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—ERBB2—urinary bladder cancer	3.12e-05	7.49e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling by GPCR—IL2—urinary bladder cancer	3.12e-05	7.48e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling by GPCR—EGFR—urinary bladder cancer	3.12e-05	7.47e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—TERT—urinary bladder cancer	3.11e-05	7.45e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.09e-05	7.4e-05	CbGpPWpGaD
Dopamine—SLC22A1—Metabolism—CREBBP—urinary bladder cancer	3.06e-05	7.35e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—ERBB2—urinary bladder cancer	2.99e-05	7.17e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling by GPCR—KRAS—urinary bladder cancer	2.98e-05	7.16e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—CXCL8—urinary bladder cancer	2.96e-05	7.1e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.95e-05	7.08e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling by GPCR—KRAS—urinary bladder cancer	2.94e-05	7.06e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling by GPCR—HRAS—urinary bladder cancer	2.94e-05	7.06e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	2.91e-05	6.98e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—RHOA—urinary bladder cancer	2.91e-05	6.97e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—CREBBP—urinary bladder cancer	2.89e-05	6.93e-05	CbGpPWpGaD
Dopamine—DRD5—Signaling Pathways—MYC—urinary bladder cancer	2.87e-05	6.89e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—RHOA—urinary bladder cancer	2.87e-05	6.88e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—IGF1—urinary bladder cancer	2.85e-05	6.84e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—FGFR3—urinary bladder cancer	2.85e-05	6.84e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling by GPCR—EGFR—urinary bladder cancer	2.84e-05	6.81e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—CXCL8—urinary bladder cancer	2.83e-05	6.8e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—IL2—urinary bladder cancer	2.83e-05	6.79e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling by GPCR—HRAS—urinary bladder cancer	2.82e-05	6.76e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.81e-05	6.75e-05	CbGpPWpGaD
Dopamine—DRD5—Signaling Pathways—EGFR—urinary bladder cancer	2.81e-05	6.73e-05	CbGpPWpGaD
Dopamine—MAOA—Metabolism—PTEN—urinary bladder cancer	2.78e-05	6.66e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—ESR1—urinary bladder cancer	2.77e-05	6.64e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—CREBBP—urinary bladder cancer	2.76e-05	6.63e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—CCND1—urinary bladder cancer	2.76e-05	6.62e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—IGF1—urinary bladder cancer	2.73e-05	6.55e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—NQO1—urinary bladder cancer	2.72e-05	6.52e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling by GPCR—EGFR—urinary bladder cancer	2.72e-05	6.51e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—IL2—urinary bladder cancer	2.71e-05	6.5e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—TYMS—urinary bladder cancer	2.7e-05	6.49e-05	CbGpPWpGaD
Dopamine—SLC22A2—Metabolism—PTGS2—urinary bladder cancer	2.69e-05	6.46e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—ERBB2—urinary bladder cancer	2.69e-05	6.46e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.69e-05	6.45e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling by GPCR—KRAS—urinary bladder cancer	2.68e-05	6.43e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—MMP9—urinary bladder cancer	2.68e-05	6.43e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.68e-05	6.42e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	2.67e-05	6.41e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	2.67e-05	6.41e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—CDKN1A—urinary bladder cancer	2.67e-05	6.4e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—PTEN—urinary bladder cancer	2.66e-05	6.39e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—ERBB2—urinary bladder cancer	2.66e-05	6.37e-05	CbGpPWpGaD
Dopamine—DRD5—Signaling Pathways—KRAS—urinary bladder cancer	2.65e-05	6.36e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.65e-05	6.36e-05	CbGpPWpGaD
Dopamine—MAOA—Metabolism—EP300—urinary bladder cancer	2.65e-05	6.35e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—CCND1—urinary bladder cancer	2.64e-05	6.34e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.64e-05	6.32e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—RHOA—urinary bladder cancer	2.61e-05	6.27e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.57e-05	6.16e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling by GPCR—KRAS—urinary bladder cancer	2.57e-05	6.15e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—MMP9—urinary bladder cancer	2.56e-05	6.15e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—GPX1—urinary bladder cancer	2.56e-05	6.14e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—CDKN1A—urinary bladder cancer	2.55e-05	6.13e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—CXCL8—urinary bladder cancer	2.55e-05	6.12e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—PTEN—urinary bladder cancer	2.55e-05	6.12e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—EP300—urinary bladder cancer	2.54e-05	6.09e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling by GPCR—HRAS—urinary bladder cancer	2.54e-05	6.08e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—CXCL8—urinary bladder cancer	2.52e-05	6.04e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	2.51e-05	6.03e-05	CbGpPWpGaD
Dopamine—SLC22A1—Metabolism—PTGS2—urinary bladder cancer	2.51e-05	6.02e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling by GPCR—HRAS—urinary bladder cancer	2.5e-05	6e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—RHOA—urinary bladder cancer	2.5e-05	6e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.49e-05	5.97e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—SRC—urinary bladder cancer	2.47e-05	5.92e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.47e-05	5.91e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.46e-05	5.9e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.46e-05	5.9e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—IL2—urinary bladder cancer	2.44e-05	5.85e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.44e-05	5.85e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.44e-05	5.85e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—EP300—urinary bladder cancer	2.43e-05	5.83e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	2.43e-05	5.82e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—ERBB2—urinary bladder cancer	2.42e-05	5.8e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—IL2—urinary bladder cancer	2.41e-05	5.77e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	2.4e-05	5.75e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	2.38e-05	5.72e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—CCND1—urinary bladder cancer	2.38e-05	5.7e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—SRC—urinary bladder cancer	2.36e-05	5.67e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	2.36e-05	5.67e-05	CbGpPWpGaD
Dopamine—DRD5—Signaling Pathways—TP53—urinary bladder cancer	2.36e-05	5.65e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.35e-05	5.65e-05	CbGpPWpGaD
Dopamine—SLC22A2—Metabolism—PTEN—urinary bladder cancer	2.35e-05	5.63e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—CCND1—urinary bladder cancer	2.35e-05	5.63e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.33e-05	5.6e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	2.31e-05	5.55e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.31e-05	5.54e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—MMP9—urinary bladder cancer	2.31e-05	5.54e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—CDKN1A—urinary bladder cancer	2.3e-05	5.52e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.3e-05	5.52e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—PTEN—urinary bladder cancer	2.29e-05	5.51e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—CXCL8—urinary bladder cancer	2.29e-05	5.5e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.29e-05	5.5e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling by GPCR—HRAS—urinary bladder cancer	2.28e-05	5.47e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—MMP9—urinary bladder cancer	2.28e-05	5.46e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—CDKN1A—urinary bladder cancer	2.27e-05	5.44e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	2.27e-05	5.44e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—PTEN—urinary bladder cancer	2.26e-05	5.43e-05	CbGpPWpGaD
Dopamine—DRD5—Signaling Pathways—HRAS—urinary bladder cancer	2.25e-05	5.41e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	2.25e-05	5.4e-05	CbGpPWpGaD
Dopamine—SLC22A2—Metabolism—EP300—urinary bladder cancer	2.24e-05	5.37e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—MYC—urinary bladder cancer	2.21e-05	5.31e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	2.19e-05	5.27e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	2.19e-05	5.26e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.19e-05	5.26e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—IL2—urinary bladder cancer	2.19e-05	5.26e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—EP300—urinary bladder cancer	2.19e-05	5.25e-05	CbGpPWpGaD
Dopamine—SLC22A1—Metabolism—PTEN—urinary bladder cancer	2.19e-05	5.25e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	2.18e-05	5.23e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.17e-05	5.21e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—EGFR—urinary bladder cancer	2.16e-05	5.19e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—EP300—urinary bladder cancer	2.16e-05	5.18e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.15e-05	5.17e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—CCND1—urinary bladder cancer	2.14e-05	5.13e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—SRC—urinary bladder cancer	2.13e-05	5.11e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—MYC—urinary bladder cancer	2.12e-05	5.08e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.11e-05	5.05e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—SRC—urinary bladder cancer	2.1e-05	5.04e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	2.1e-05	5.03e-05	CbGpPWpGaD
Dopamine—SLC22A1—Metabolism—EP300—urinary bladder cancer	2.09e-05	5.01e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.08e-05	5e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.08e-05	5e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—MMP9—urinary bladder cancer	2.08e-05	4.98e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—EGFR—urinary bladder cancer	2.07e-05	4.97e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—CDKN1A—urinary bladder cancer	2.07e-05	4.96e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—PTEN—urinary bladder cancer	2.06e-05	4.95e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—KRAS—urinary bladder cancer	2.04e-05	4.91e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	2.04e-05	4.9e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	2.03e-05	4.87e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.99e-05	4.78e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	1.98e-05	4.76e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.98e-05	4.74e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	1.97e-05	4.73e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—EP300—urinary bladder cancer	1.97e-05	4.72e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.96e-05	4.7e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—KRAS—urinary bladder cancer	1.96e-05	4.7e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	1.93e-05	4.62e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.92e-05	4.6e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	1.91e-05	4.59e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—SRC—urinary bladder cancer	1.91e-05	4.59e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—MYC—urinary bladder cancer	1.91e-05	4.57e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	1.88e-05	4.51e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—MYC—urinary bladder cancer	1.88e-05	4.51e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—EGFR—urinary bladder cancer	1.87e-05	4.47e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—IL2—urinary bladder cancer	1.84e-05	4.42e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.84e-05	4.42e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—EGFR—urinary bladder cancer	1.84e-05	4.42e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.84e-05	4.41e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	1.83e-05	4.39e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—TP53—urinary bladder cancer	1.82e-05	4.36e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	1.8e-05	4.31e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—KRAS—urinary bladder cancer	1.76e-05	4.23e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.76e-05	4.23e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.75e-05	4.19e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	1.74e-05	4.18e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—TP53—urinary bladder cancer	1.74e-05	4.17e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—KRAS—urinary bladder cancer	1.74e-05	4.17e-05	CbGpPWpGaD
Dopamine—HTR7—Signaling Pathways—HRAS—urinary bladder cancer	1.74e-05	4.17e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.74e-05	4.17e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	1.73e-05	4.16e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—MYC—urinary bladder cancer	1.71e-05	4.11e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.69e-05	4.06e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.68e-05	4.03e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—EGFR—urinary bladder cancer	1.68e-05	4.02e-05	CbGpPWpGaD
Dopamine—DRD4—Signaling Pathways—HRAS—urinary bladder cancer	1.66e-05	3.99e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—EP300—urinary bladder cancer	1.65e-05	3.96e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	1.64e-05	3.93e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—SRC—urinary bladder cancer	1.61e-05	3.85e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	1.6e-05	3.85e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—KRAS—urinary bladder cancer	1.58e-05	3.8e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—TP53—urinary bladder cancer	1.57e-05	3.76e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—TP53—urinary bladder cancer	1.55e-05	3.71e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	1.52e-05	3.64e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.51e-05	3.61e-05	CbGpPWpGaD
Dopamine—DRD1—Signaling Pathways—HRAS—urinary bladder cancer	1.5e-05	3.59e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.49e-05	3.58e-05	CbGpPWpGaD
Dopamine—DRD3—Signaling Pathways—HRAS—urinary bladder cancer	1.48e-05	3.55e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—MYC—urinary bladder cancer	1.44e-05	3.45e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.43e-05	3.44e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	1.41e-05	3.38e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—TP53—urinary bladder cancer	1.41e-05	3.38e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.39e-05	3.32e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.37e-05	3.3e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	1.35e-05	3.23e-05	CbGpPWpGaD
Dopamine—ADRB1—Signaling Pathways—HRAS—urinary bladder cancer	1.35e-05	3.23e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	1.33e-05	3.19e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.31e-05	3.15e-05	CbGpPWpGaD
Dopamine—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	1.29e-05	3.09e-05	CbGpPWpGaD
Dopamine—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.25e-05	3.01e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.21e-05	2.9e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.2e-05	2.87e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—TP53—urinary bladder cancer	1.18e-05	2.84e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.17e-05	2.82e-05	CbGpPWpGaD
Dopamine—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.15e-05	2.77e-05	CbGpPWpGaD
Dopamine—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.14e-05	2.74e-05	CbGpPWpGaD
Dopamine—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	1.13e-05	2.71e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.02e-05	2.46e-05	CbGpPWpGaD
Dopamine—CYP1A2—Metabolism—EP300—urinary bladder cancer	9.77e-06	2.34e-05	CbGpPWpGaD
